Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





LumiraDx Highlights Next-Generation Point of Care Solutions at MEDLAB Middle East Virtual Event

By LabMedica International staff writers
Posted on 21 Jun 2021
LumiraDx (London, UK) attended the virtual event of this year’s Medlab Middle East, the leading medical laboratory exhibition in the region for over 20 years. More...
The event brought together over 23,000 medical laboratory, healthcare and trade professionals from more than 140 countries.

In 2021 Medlab Middle East was run as a hybrid event and once again co-locating with Arab Health, bringing together the healthcare and laboratory communities. This year’s online event allowed delegates to network with industry peers, meet virtually, explore the latest products and attend educational sessions. LumiraDx exhibited online for the first time at Medlab Middle East and introduced its transformational point of care solution, the innovative LumiraDx Platform which is designed to perform a broad menu of tests, including infectious disease, cardiovascular disease, diabetes, and coagulation disorders and deliver lab-comparable performance with results in less than 12 minutes. The next generation point of care diagnostic system combines a small, portable instrument; microfluidic test strip; simple, standardized workflow; and seamless, secure digital connectivity to the Cloud and hospital IT systems. It is designed to be affordable and accessible for healthcare providers globally, and to strengthen community-based healthcare.

LumiraDx also highlighted its COVID-19 testing solutions at MEDLAB Middle East 2021, including its recently launched SARS-CoV-2 Antigen Test for use on the LumiraDx Platform which delivers results in 12 minutes with 97.6% PPA to an EUA approved RT-PCR method within the first 12 days of symptom onset. The use of a LumiraDx SARS-CoV-2 Ag Test on the LumiraDx Instrument enables the physician to verify infection quickly, begin proper treatment and to initiate isolation precautions helping prevent further spread of infection. Also on display was the LumiraDx SARS-CoV-2 Ag Pool Test, a rapid microfluidic immunofluorescence assay for the qualitative detection of the nucleocapsid protein antigen in nasal or nasopharyngeal swab specimens pooled from up to five individuals suspected of COVID-19 or up to five asymptomatic individuals. Used with the LumiraDx Platform, the test offers a rapid, scalable and cost-effective screening solution for infectious individuals. The company also showcased the LumiraDx SARS-CoV-2 Ab Test, a microfluidic immunofluorescence assay for the qualitative detection of total antibodies to SARS-CoV-2 in human whole blood (capillary fingerstick or venous), plasma or serum for indication of recent or prior infection. Used with the LumiraDx Platform, the test delivers rapid results at the point of care.

Related Links:
LumiraDx


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.